Savvy Advisors Inc. Buys Shares of 5,206 Incyte Corporation $INCY

Savvy Advisors Inc. bought a new position in Incyte Corporation (NASDAQ:INCY) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 5,206 shares of the biopharmaceutical company’s stock, valued at approximately $442,000.

Several other institutional investors have also modified their holdings of the stock. Bank of Nova Scotia grew its holdings in shares of Incyte by 0.7% in the second quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock valued at $1,160,000 after purchasing an additional 124 shares during the period. MAI Capital Management boosted its holdings in Incyte by 19.9% in the 2nd quarter. MAI Capital Management now owns 754 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 125 shares during the last quarter. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Incyte by 0.9% in the 3rd quarter. Atlantic Edge Private Wealth Management LLC now owns 14,556 shares of the biopharmaceutical company’s stock valued at $1,235,000 after buying an additional 125 shares during the period. E Fund Management Co. Ltd. increased its holdings in shares of Incyte by 0.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 19,912 shares of the biopharmaceutical company’s stock worth $1,356,000 after buying an additional 158 shares during the last quarter. Finally, Wealthfront Advisers LLC increased its holdings in shares of Incyte by 2.4% during the 2nd quarter. Wealthfront Advisers LLC now owns 7,366 shares of the biopharmaceutical company’s stock worth $502,000 after buying an additional 171 shares during the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 results & guidance: Incyte reported Q4 revenue above expectations and outlined 10–13% revenue growth for 2026, citing pipeline expansion and new product launches — a clear near-term growth signal that investors rewarded. Incyte outlines 10–13% revenue growth for 2026
• Positive Sentiment: Analyst tone: Coverage pieces and aggregate analyst commentary remain constructive—Wall Street highlights steady growth and the pipeline, helping underpin sentiment despite the EPS miss. Do Wall Street Analysts Like Incyte Corporation Stock?
• Positive Sentiment: Asset monetization: Incyte sold the Wilmington Bracebridge towers to BPG, a real-estate disposition that should free cash / simplify the corporate footprint — modestly positive for cash flow and capital allocation. Incyte’s big downtown Wilmington move…
• Neutral Sentiment: Market commentary: Several pieces ask whether INCY’s ~43% one‑year run makes it “too late” to buy; these are opinion/valuation discussions that influence positioning but don’t change fundamentals immediately. Is It Too Late To Consider Incyte After Its 43% One Year Rally
• Neutral Sentiment: Media flow: Earnings-call highlights and coverage (transcripts, midday movers) are being digested; they offer color but largely reiterate the same beats/risks. Incyte Q4 Earnings Call Highlights
• Neutral Sentiment: Short-interest data appears inconsistent/erroneous in recent filings (reports show zero shares / NaN changes), so short-interest signals aren’t informative right now.
• Negative Sentiment: Opzelura guidance & Jakafi patent fears: A weaker 2026 revenue forecast for Opzelura raised renewed concerns about franchise vulnerability and potential spillover to Jakafi patent litigation/renewed competitive risk. Opzelura weak 2026 forecast heightens Jakafi patent concerns
• Negative Sentiment: EPS miss & share reaction: INCY missed on EPS for the quarter, which prompted a post‑earnings gap down in some sessions and is a key reason for caution despite the revenue beat. Shares Gap Down After Earnings Miss
• Negative Sentiment: Regulatory/pricing risk: Management flagged exposure to evolving U.S. drug‑pricing policies (e.g., Most Favored Nation‑style measures), which could pressure profitability if enacted. Profit Outlook Threatened by Pricing Policies

Incyte Price Performance

INCY stock opened at $101.10 on Friday. The business’s fifty day moving average price is $101.73 and its 200 day moving average price is $94.19. Incyte Corporation has a 12-month low of $53.56 and a 12-month high of $112.29. The company has a current ratio of 3.32, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $20.12 billion, a PE ratio of 15.77, a P/E/G ratio of 0.61 and a beta of 0.82.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.35 billion. Incyte had a net margin of 25.03% and a return on equity of 26.34%. The business’s revenue was up 27.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.43 earnings per share. On average, sell-side analysts anticipate that Incyte Corporation will post 4.86 EPS for the current year.

Insider Buying and Selling at Incyte

In other Incyte news, insider Thomas Tray sold 2,774 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $100.00, for a total value of $277,400.00. Following the completion of the transaction, the insider owned 22,973 shares in the company, valued at $2,297,300. The trade was a 10.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Steven H. Stein sold 20,105 shares of the company’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $102.51, for a total value of $2,060,963.55. Following the sale, the executive vice president directly owned 63,129 shares in the company, valued at $6,471,353.79. This represents a 24.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 95,225 shares of company stock worth $9,519,745. 17.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on INCY shares. TD Cowen reiterated a “buy” rating on shares of Incyte in a report on Tuesday, January 13th. Truist Financial set a $103.00 price target on Incyte in a research note on Wednesday, December 24th. Zacks Research cut Incyte from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Wells Fargo & Company cut their price objective on Incyte from $107.00 to $101.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $135.00 target price on shares of Incyte in a research report on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $103.94.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.